On October 21, 2021, the Food and Drug Department (FDD) of the Lao Ministry of Health officially approved Niraparib tablets manufactured by TLPH under the trade name Nizela for sale. This is the fifth first-line cancer drug approved by TLPH in 2021.

Nirapali is a PARP inhibitor acquired by GSK through its acquisition of TESARO. PARP inhibitors are targeted therapies that kill cancer cells by inhibiting PARP-mediated DNA damage repair response (DDR). Using the principle of "synthetic lethality", they can kill cancer cells while leaving healthy cells unaffected.

On October 24, 2019, the FDA approved Niraparib for expanded indications in patients with advanced ovarian cancer, fallobal cancer, or primary peritoneal cancer who are homologous recombination defect (HRD) positive and have received three or more chemotherapy treatments.

TLPH is highly focused on the field of cancer treatment for women. In 2017, TLPH  Olaparib capsule was put on the market and received good market response. In September 2021, olaparib tablets were launched; Nirapali was approved in October. At this point, TLPH has both olipanib (capsule + tablet) and nilaparib as PARP inhibitors for first-line treatment.